
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems Inc. is witnessing a positive financial trajectory, with gross margins expanding significantly from 48.8% in FY22 to an estimated 53.4% by 2025, reflecting improved operational efficiency. The company's overall revenue has grown approximately 11%, supported by a robust 11% increase in its Cardiovascular segment, which continues to be the primary revenue driver, bolstered by increased physician reimbursement rates that may enhance product adoption. Additionally, the Endoscopy segment has demonstrated strong performance, with revenues reaching $20.1 million and marking a 15% growth, indicating a favorable trend towards increased procedure volumes and pricing advantages.
Bears say
Merit Medical Systems has faced notable challenges in its revenue growth, particularly with OEM revenue falling short of expectations at $48.1 million compared to the anticipated $58.3 million. Critical risks include worse-than-expected margin performance, free cash flow issues, and slowed growth in key markets like China, which has shown a decline in revenue due to value-based purchasing headwinds and macroeconomic pressures. The company's bear case scenario suggests a revenue growth rate of 5% or lower, driven by poor performance from recent acquisitions and new product launches, potentially leading to further operating margin contraction and earnings falling below consensus estimates.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares